BCAR4: A Potential Drug Target and Biomarker for Breast Cancer

Target Name: BCAR4

NCBI ID: G400500

BCAR4

Other Name(s): Breast cancer antiestrogen resistance 4 protein | BCAR4 variant 1 | breast cancer anti-estrogen resistance 4 | Breast cancer anti-estrogen resistance 4, transcript variant 1 | HCG1814062, isoform CRA_a

BCAR4: A Potential Drug Target and Biomarker for Breast Cancer

Breast cancer is a leading cause of cancer-related deaths in women worldwide. Despite advances in treatment, the survival rate for breast cancer remains poor. One of the major challenges in breast cancer treatment is the development of resistance to drugs, particularly antiestrogens. Women with breast cancer who do not respond to treatment may have limited treatment options and a poor prognosis.

BCAR4 is a protein that has been identified as a potential drug target or biomarker for breast cancer. It is a transmembrane protein that is expressed in various tissues, including breast tissue, and is involved in cell signaling. The BCAR4 protein has been shown to play a role in the development and progression of breast cancer, and is a promising target for researchers to explore for new treatments.

BCAR4 function
BCAR4 is a member of the TGF-β signaling pathway, a well-established pathway that plays a role in cell growth, differentiation, and survival. The TGF-β pathway is involved in many cellular processes, including cell signaling, cell migration, and angiogenesis. BCAR4 is a critical component of the TGF-β pathway in breast tissue, and is involved in the regulation of cell proliferation, survival, and angiogenesis.

BCAR4 is expressed in various tissues, including breast tissue, and has been shown to play a role in the development and progression of breast cancer. Studies have shown that high levels of BCAR4 expression are associated with poor prognosis in breast cancer patients. Additionally,BCAR4 has been shown to be a potential biomarker for breast cancer, with higher levels of BCAR4 expression being associated with poor prognosis.

Drug targeting
Drug targeting is a promising strategy for treating breast cancer. By targeting specific proteins involved in the development and progression of breast cancer, researchers can inhibit these proteins and disrupt the signaling pathways that drive cancer growth. BCAR4 is a protein that has been shown to be a potential drug target in breast cancer.

One approach to targeting BCAR4 is to use small molecules, such as inhibitors, to inhibit its activity. Small molecules have been shown to be effective in inhibiting the activity of BCAR4 in cell culture and animal models of breast cancer. Additionally, blockade of BCAR4 has been shown to be an effective way to treat breast cancer in cell culture and animal models.

Another approach to targeting BCAR4 is to use monoclonal antibodies (MCAs), which are laboratory-produced antibodies that can be used to target specific proteins. MCAs have been shown to be effective in targeting BCAR4 and inhibiting its activity in cell culture and animal models of breast cancer.

BCAR4 as a biomarker
BCAR4 has also been shown to be a potential biomarker for breast cancer. Studies have shown that higher levels of BCAR4 expression are associated with poor prognosis in breast cancer patients. Additionally, levels of BCAR4 have been shown to be a good predictor of breast cancer recurrence.

The BCAR4 gene has also been shown to be expressed in various tissues, including breast tissue, and has been shown to play a role in the development and progression of breast cancer. This suggests that BCAR4 may be a useful biomarker for breast cancer, and that it may be possible to use it as a diagnostic tool for breast cancer.

Conclusion
In conclusion, BCAR4 is a protein that has been identified as a potential drug target or biomarker for breast cancer. Its role in the TGF-β signaling pathway and its expression in various tissues make it a promising target for researchers to explore for new treatments. Additionally, BCAR4 has been shown to be a potential biomarker for breast cancer, with higher levels of BCAR4 expression being associated with poor prognosis. Further research is needed to fully understand the role of BCAR4 in breast cancer and to develop effective treatments.

Protein Name: Breast Cancer Anti-estrogen Resistance 4

The "BCAR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCAR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets